JAN 17, 2017 10:27 AM PST

Epigenetics Initiate Pancreatic Cancer Metastasis

Pancreatic cancer is one of the deadliest cancers observed worldwide. Once it is diagnosed, metastasis to other organs has most likely already occurred, resulting in a 94% mortality rate. With a recent increase in new cases of pancreatic cancer, it is predicted that it will be the second leading cause of death, following lung cancer, by 2020.

Cancer metastasis has been a tough puzzle for researchers to crack. Once a tumor has grown in one site, something changes in a part of the tumor, initiating migration and regrowth at a different location. A multidisciplinary group of scientists has recently uncovered a new mechanism and pathway used by metastatic cancer cells in pancreatic cancer.

Pancreatic anatomy

Based on research done by a collaborating lab on pancreatic tumor samples taken from eight patients immediately after their death, the group discovered an epigenetic connection to metastatic initiation. The collaborating lab had been looking for direct genetic mutations and found no major differences in metastatic tumor cell DNA compared to the original tumor cells.

However, by opening up the search to any epigenetic changes in these same samples, the group, led by Andrew Feinberg, M.D., Bloomberg Distinguished Professor of Epigenetics at The Johns Hopkins University, found not only several epigenetic changes in large blocks of the genome but also pinpointed a priming pathway and specific protein player in causing new cells to break off and migrate to alternate sites.

The epigenome incorporates reversible chemical and structural changes to DNA and its included histones. Instead of altering the DNA sequence itself, epigenetic changes can govern gene activation or silencing. In order to examine the epigenome in the tumor samples, the team used tissue staining, histone analysis and whole-genome sequencing.

The epigenetic changes they found in large blocks of the genome seemed to only occur in the metastatic cells that migrated to new locations and in the subset of cells in the primary tumor that the metastatic cells broke apart from. There were no major epigenetic changes in the primary tumor cells.

"Distant metastases have to travel long distances along the 'highways' of the blood vessels, land in a good spot and colonize, while local metastases just pinch off the primary tumor and go a short distance on 'familiar side roads,' so they are usually more similar to the primary tumor," explains Christine Iacobuzio-Donahue, M.D., Ph.D., professor of pathology at Memorial Sloan Kettering Cancer Center.

Upon finding such dramatic epigenetic alterations, the team further investigated what functions the affected genes were involved in and how these changes might be controlled. Cancer cell processes such as increased glucose metabolism and enhanced migration pathways are somewhat understood. However, finding how these enhancements are made in the first place has proven more difficult.

By looking into specific biochemical mechanisms the cells might use to increase their glucose metabolism, specifically in metastasized cells compared to their primary tumor counterparts, the researchers found that metastasized cells use the pentose phosphate pathway to convert glucose efficiently and that 6-phosphogluconate dehydrogenase was a primary player.

The discovery of this pathway and primary protein in metastatic-specific metabolism could underline the difference between the slow growth of a primary tumor and the relatively fast growth and migration of secondary tumors.

While the findings provide a significant new understanding of the specific metabolism and growth of metastatic tumors, there is much work to be done to learn more about how blocking the pathway might be used in treatment.

In addition, these epigenetic changes in large blocks of the genome could potentially be found across other cancers as well, providing other possible avenues for treatment of multiple cancer types. "Although we haven't tested this idea yet, we know that similar epigenetic regions are important in other types of cancer, such as colon cancer, so it's likely that these large-scale epigenetic changes are occurring in them too," says Feinberg.

Sources: Medxpress, Nature Genetics

About the Author
  • I love all things science and am passionate about bringing science to the public through writing. With an M.S. in Genetics and experience in cancer research, marketing and technical writing, it is a pleasure to share the latest trends and findings in science on LabRoots.
You May Also Like
NOV 19, 2018
Genetics & Genomics
NOV 19, 2018
Revealing an Unexpected Role for RNA in DNA Repair
When both strands of DNA break, it must be repaired or the cell will die....
NOV 24, 2018
Videos
NOV 24, 2018
Bats may Hold the Secret to Longevity
Some bats can live for up to 41 years, and many have a very healthy life....
NOV 28, 2018
Videos
NOV 28, 2018
What critics think about the first gene-edited babies
Chinese scientist He Jiankui took advantage of the International Human Genome Editing Summit in Hong Kong to publicize the results of his Crispr-Cas9 trial...
DEC 11, 2018
Immunology
DEC 11, 2018
Autoimmunity Caused By Genetic Mutation
Research reveals a genetic mutation causes a protein binding site to alter its structure resulting in the development of chronic inflammation and autoimmunity...
DEC 12, 2018
Videos
DEC 12, 2018
Why Don't We Clone Extinct or Endangered Animals?
While estimates about the number of species that go extinct vary widely, one thing is certain: we can list many animals that have gone extinct....
DEC 20, 2018
Videos
DEC 20, 2018
A Genetic Test for Sociability in Dogs
It may be possible to swab a dog's cheek and do a genetic test to see if it would make a good service dog....
Loading Comments...